IOL Chemicals and Pharmaceuticals share news, announcements and annual reports
NSE: IOLCPBSE: 524164Pharmaceuticals & BiotechnologySmall Cap
IOL Chemicals and Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1991 on BSE, Nov 2010 on NSE
Last close ₹177.65down ₹7.28 (3.94%)BSE ₹177.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹184.93.
30 Oct: open ₹186.40, high ₹186.40, low ₹176.02
52-week range of traded prices to 30 Oct 2026
₹67.19Low, 16 Mar 2026₹224.00High, 7 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,215 Cr1,024th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 25.66
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.71
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.56%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 18,08,91234.0% delivered
IOL Chemicals and Pharmaceuticals share news and announcements
709 announcements, routine notices left out, newest first. Page 14 of 15.
Nov 2013
1 Nov · Board meeting
Inter-alia to consider the un-audited financial results of the Company for the quarter and half year ended September 30, 2013.
Oct 2013
1 Oct · Disclosure of Voting Pattern - Clause 35A
Sep 2013
Aug 2013
14 Aug · Meeting
Annual General Meeting of the members of the Company will be held on September 28, 2013. Further, the Register of Members and the Share Transfer Books will remain closed from September 24, 2013 to September 28, 2013 (both days inclusive) for the purpose of Annual General Meeting of the Company.5 Aug · Board meeting
Inter-alia to consider the un-audited financial results of the Company for the quarter ended June 30, 2013.
Jul 2013
May 2013
28 May · Board meeting
Board of Directors of the Company at its meeting held on May 27, 2013 has considered and approved the following matters:(1) Considered and approved the redesignation of Mr. Vijay Kumar Garg as joint Managing Director of the Company.(2) Considered and approved the resignation of Mr. Varinder Gupta from Chairman of the Board of the Company.(3) Considered and approved the appointment of Dr. M. A. Zahir as Chairman of the Board of the Company.27 May · Results
20 May · Board meeting
Inter-alia to consider and approve the audited financial results of the Company for the quarter and the financial year ended March 31, 2013.
Mar 2013
Feb 2013
5 Feb · Board meeting
Inter-alia to consider the un-audited financial results of the Company for the quarter ended December 31, 2012.
Jan 2013
Dec 2012
Nov 2012
12 Nov · Board meeting
Oct 2012
31 Oct · Board meeting
Inter-alia to consider the un-audited financial results of the Company for the quarter and half year ended September 30, 2012.
Sep 2012
Aug 2012
17 Aug · Board meeting
Board of Directors in its meeting held on August 14, 2012 has approved the following:- 1. Re-appointment of Sh. Varinder Gupta as Managing Director of the Company with effect from September 01, 2012.14 Aug · Meeting
Annual General Meeting of the members of the Company will be held on September 29, 2012. Further, the Register of Members and the Share Transfer Books will remain closed from September 25, 2012 to September 29, 2012 (both days inclusive).6 Aug · Board meeting
Inter-alia to consider the un-audited financial results of the Company for the quarter ended June 30, 2012.
May 2012
30 May · Results
21 May · Board meeting
Inter-alia to consider and approve the audited financial results of the Company for the quarter and the financial year ended March 31, 2012.2 May · Business
Share Allotment Committee of the Board of Directors in its meeting held on May 02, 2012 allotted 4,34,500 equity shares of Rs. 10/- each to the shareholders of G Drugs and Pharmaceuticals Limited in terms of the Exchange Ratio 1 (one) equity share of the Company of the face value of Rs. 10/- each credited as fully paid up at par for every 20 (Twenty) fully paid up equity shares of Rs.10/- each held by such equity shareholders of the G Drugs and Pharmaceuticals Limited as sanction by BIFR Order dated March 15, 2012, which will be locked in for a period of three years from the date of allotment. Consequent upon the issue of the above 4,34,500 equity shares, the total paid-up capital of the company stands increased to 2,61,51,164 fully paid equity shares of Rs. 10/- each.
Apr 2012
23 Apr · Updates
Company has fixed May 01, 2012 as the Record Date for the purpose of determining the shareholders of G Drugs and Pharmaceuticals Limited (Transferor Company), who would be entitled to the Shares of IOL Chemicals and Pharmaceuticals Limited (Transferee Company), in terms of the Exchange Ratio 1 (one) equity share of Transferee Company of the face value of Rs. 10/- credited as fully paid up at par for every 20 (Twenty) fully paid up equity shares of Rs. 10/- held by such equity shareholders of the Transferor Company as sanction by BIFR Order dated March 15, 2012.3 Apr · Board meeting
Board of Directors in its meeting held on March 31, 2012 has approved the following matters: (1) The resignation of Sh Kanwal Pushkarnath Pandita as director of the Company w.e.f March 31, 2012. (2) The resignation of Smt Dimple Gupta as director of the Company w.e.f. March 31, 2012.(3) Approved the appointment of Sh Narender Kumar Pundir as Additional Director and Director (Commercial) w.e.f. March 31, 2012. He has about 26 years experience in commercial activities of chemical products and has also international exposure in the industry. He holds masters degree in science and post graduate diploma in business management.
Feb 2012
6 Feb · Board meeting
Inter-alia to consider the un-audited financial results of the Company for the quarter ended December 31, 2011.
Dec 2011
Nov 2011
8 Nov · Board meeting
Inter-alia to consider the un-audited financial results of the Company for the quarter/half year ended September 30, 2011.
Sep 2011
5 Sep · Meeting
Register of Members and the Share Transfer of Books of the Company will remain closed from September 20, 2011 to September 24, 2011 (both days inclusive) for the purpose of Annual General Meeting of the Company to be held on September 24, 2011.
Aug 2011
12 Aug · Results
4 Aug · Board meeting
Inter-alia to consider the un-audited financial results of the Company for the quarter ended June 30, 2011.
Jul 2011
20 Jul · Updates
15,00,000 warrants were allotted on preferential basis under SEBI (issue of Capital and Disclosure Requirements) Regulation, 2009 on January 16, 2010; 10,00,000 Warrants to NCG Enterprises Limited and 5,00,000 warrants to OL Lifesciences Limited. As the Allottees have not exercised their option to subscribe the aforesaid shares with respect to above warrants with in prescribed period i.e. July 15, 2011, the amount of advance @ 25% of per warrant stands forfeited in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2009.11 Jul · Management
Board of Directors in its meeting held on July 11, 2011 has approved the following matters : (1) Considered and approved the resignation of Sh R K Thukral as the Executive director of the Company with effect from July 11, 2011; (2) The Board has approved the appointment of Sh Vijay Singla, BE - Chemical Engineer as Additional Director and Director (Works) with effect from July 11, 2011.
Jun 2011
28 Jun · Updates
Company's In-House Research & Development Unit has got successfully recognition from DSIR (Deptt. of Scientific & Industrial Research), Ministry of Science & Technology, New Delhi.
May 2011
23 May · Management
Board of Directors of the Company at its meeting held on May 21, 2011 has considered and approved the resignation of Dr (Mrs) H K Bal as the director of the Company.23 May · Results
16 May · Board meeting
Inter-alia to consider the audited financial results of the company for the year ended March 31, 2011.
Apr 2011